The treatment of neurological disorders has entered a new period of optimism.New insights into the underlying mechanisms of previously untreatable disorders, has led to a flurry of activity and a host of new drugs in development.However, the major bottleneck, and the biggest barrier to commercial expansion, is clinical progression.Drug development for CNS is still a risky business. With 100s of millions of Euros being spent on every clinical trial, it is now more important than ever to capitalise on research progress. The key to success is translating our ever growing knowledge of CNS disorders into well constructed, efficient and most importantly conclusive clinical trials.Inspired by the world's leading CNS drug developers (including Merck Serono, Johnson & Johnson, Novartis, AstraZeneca, Pfizer, F. Hoffman-La Roche, UCB, Merck & Co, Abbott and many other pioneering biotechs) you'll find an agenda that delivers practical value and provides you with a forum for frank and honest discussion.